While these findings suggest that treatments that reduce PPARγ activity suppress, whereas treatments that increase PPARγ activity, enhance breast cancer cell growth, the possibility exists that these effects are mediated, at least in part, through PPARγ-independent mechanism(s). Here, PPARG is linked to breast carcinoma.